Important Information for Investors: Geron Corporation Class Action Lawsuit
On March 21, 2025, the law firm of Robbins Geller Rudman & Dowd LLP announced that purchasers or acquirers of Geron Corporation (GERN) securities between February 28, 2024, and February 25, 2025, both dates inclusive (the “Class Period”), have until May 12, 2025, to seek appointment as lead plaintiff in a class action lawsuit against Geron Corporation. The lawsuit, captioned Dabestani v. Geron Corporation et al., alleges that the company and certain executives violated the Securities Exchange Act of 1934 by making false and misleading statements and failing to disclose material information.
Background
Geron Corporation is a biotechnology company engaged in the discovery, development, and commercialization of therapeutics for cancer and aging. The company’s lead product candidate, imetelstat, is a first-in-class epigenetic modulator being developed for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Allegations in the Lawsuit
The complaint alleges that during the Class Period, Geron and certain executives made false and misleading statements and failed to disclose material information regarding the safety and efficacy of imetelstat. Specifically, the complaint alleges that the defendants failed to disclose that imetelstat was not demonstrating the expected efficacy in clinical trials, and that the results of a Phase 3 trial were not statistically significant. The complaint also alleges that the defendants failed to disclose that imetelstat was associated with a higher risk of thrombotic events than previously disclosed.
Impact on Individual Investors
If you purchased or acquired Geron securities during the Class Period and suffered losses, you may be eligible to seek appointment as lead plaintiff in the Geron class action lawsuit. As a lead plaintiff, you would act on behalf of all members of the class in the lawsuit. The lead plaintiff will be responsible for making important decisions regarding the litigation and working with the law firm to represent the interests of the class. If you wish to discuss your potential role as a lead plaintiff, please contact Robbins Geller Rudman & Dowd LLP.
Impact on the World
The Geron class action lawsuit has significant implications for the biotechnology industry as a whole. The allegations in the lawsuit highlight the importance of transparency and accuracy in reporting clinical trial results, particularly for companies developing potential breakthrough treatments. The lawsuit also underscores the need for investors to carefully evaluate the safety and efficacy data of biotech companies before making investment decisions.
Conclusion
The Geron class action lawsuit is an important development for investors in the biotechnology sector. If you purchased or acquired Geron securities during the Class Period and suffered losses, you may be eligible to seek appointment as lead plaintiff in the lawsuit. The lawsuit highlights the importance of transparency and accuracy in reporting clinical trial results, and underscores the need for investors to carefully evaluate the safety and efficacy data of biotech companies before making investment decisions. For more information, please contact Robbins Geller Rudman & Dowd LLP.
- Geron Corporation announced a class action lawsuit against the company and certain executives.
- The lawsuit alleges that the defendants made false and misleading statements and failed to disclose material information regarding the safety and efficacy of imetelstat.
- Individual investors who purchased or acquired Geron securities during the Class Period may be eligible to seek appointment as lead plaintiff in the lawsuit.
- The lawsuit has significant implications for the biotechnology industry and underscores the importance of transparency and accuracy in reporting clinical trial results.
